Development and validation of RP-HPLC method for simultaneous quantification of the anticancer agents, nilotinib and sorafenib: Application in In-vitro analysis
- سال انتشار: 1401
- محل انتشار: فصلنامه پیشرفت درتحقیقات بیوشیمی و شیمی، دوره: 5، شماره: 1
- کد COI اختصاصی: JR_PCBR-5-1_004
- زبان مقاله: انگلیسی
- تعداد مشاهده: 167
نویسندگان
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Department of Human Ecology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Department of Chemistry, Faculty of Sciences, Tarbiat Modares University, Tehran, Iran
Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medial Sciences.
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
چکیده
In this research, a reversed phase high performance liquid chromatographic method was developed for the simultaneous determination of two tyrosine kinase inhibitors, nilotinib and sorafenib. Separation was performed on an Agilent C۱۸ column (۴.۶×۲۵۰ mm, ۵µm) with mobile phase composition of potassium dihydrogen phosphate buffer (۲۵ mM, pH ۴.۲) and acetonitrile (۳۵:۶۵ v/v) at ۱.۲ mL/min with UV detection at ۲۶۵ nm. Specificity, linearity, precision, accuracy, and robustness of the proposed method were all assessed. Nilotinib and sorafenib had estimated retention times of ۵.۱ and ۵.۹ minutes, respectively. Linear concentration ranges for nilotinib and sorafenib, were determined as ۰.۰۵-۱ µg/mL and ۱۰-۴۵ µg/mL with comparable coefficient correlations (۰.۹۹۹). For nilotinib and sorafenib, the limits of detection (LOD) were determined as ۰.۰۳۰ and ۰.۰۲۰ µg/mL, while the limits of quantification (LOQ) were ۰.۱۰۱ and ۰.۰۶۹ µg/mL respectively.کلیدواژه ها
HPLC, Nilotinib, sorafenib, Determination, tyrosine kinase inhibitorاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.